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Summary
Objective: Marrow-stimulation techniques are used by surgeons to repair cartilage lesions although consistent regeneration of hyaline carti-
lage is rare. We have shown previously that autologous blood can be mixed with a polymer solution containing chitosan in a glycerol phos-
phate (GP) buffer (chitosaneGP), and that implantation of this polymer/blood composite onto marrow-stimulated chondral defects in rabbit and
sheep leads to the synthesis of more chondral repair tissue with greater hyaline character compared to marrow-stimulation alone. In the cur-
rent study, we examined the modulation of cell recruitment and repair tissue characteristics at early post-surgical time points (from day 1 to 56)
in a rabbit model to elucidate potential mechanisms behind this improved repair outcome.
Design: Thirty-three skeletally mature New Zealand White rabbits underwent bilateral arthrotomies, with each trochlea receiving a cartilage
defect (3.5 mm 4.5 mm) bearing four microdrill holes (0.9 mm diameter, w4 mm deep) into the subchondral bone. One defect per rabbit
was treated with a chitosaneGP/blood implant, while the other defect was left as a microdrilled control. Repair tissues were stained by his-
tochemistry, for collagen types I, II, and X by immunohistochemistry and analyzed using quantitative stereological tools.
Results: Histological analyses demonstrated that control defects followed a typical healing sequence observed previously in marrow-stimula-
tion animal models while chitosaneGP/blood implants led to three signiﬁcant modiﬁcations in the healing sequence at early stages: (1) in-
creased inﬂammatory and marrow-derived stromal cell recruitment to the microdrill holes, (2) increased vascularization of the provisional
repair tissue in the microdrill holes, and (3) increased intramembranous bone formation and subchondral bone remodeling (BR).
Conclusions: These results suggest that the greater levels of provisional tissue vascularization and BR activity are main factors supporting
improved cartilage repair when chitosaneGP/blood implants are applied to marrow-stimulated cartilage lesions.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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saline, PDGF Platelet-derived growth factor.
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SocietyIntroduction
Lesions of articular cartilage that extend into subchondral
bone have access to multiple cell types that can migrate
into the chondral zone of the lesion and synthesize a repair
tissue1,2. Orthopedic surgeons have developed marrow-
stimulation techniques, such as abrasion arthroplasty3, dril-
ling4 and microfracture5 in order to provide access channels
to marrow-derived blood and cells and consequently initiate
a wound repair response in cartilage defects. These surgi-
cal techniques have met with some success6 but are
thought to mainly produce ﬁbrocartilagenous repair with lim-
ited mechanical properties and durability1.
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the formation of a blood clot7 that establishes hemostasis,
and generates multiple signals leading to cell recruitment
and synthesis of a provisional scaffold for cell migration.
Since marrow-stimulation alone does not reproducibly
lead to the formation of hyaline repair cartilage, it may be
concluded that these procedures do not generate an opti-
mal setting for effective cartilage repair. One potential limi-
tation of these procedures is that the resident blood clot
resulting from marrow-stimulation retracts to a small per-
centage of its original volume via a platelet-mediated
process8,9 and may be subsequently removed by ﬂuid irri-
gation. Stabilizing this critical blood clot in the cartilage
lesion could improve cartilage repair by providing a physical
and chemical environment suitable for migration of progen-
itor cells and synthesis of repair tissue. With this in mind, we
have recently adopted an approach to improve cartilage re-
pair by mixing solubilized chitosan, a biodegradable throm-
bogenic polymer, with autologous blood. This polymer/
blood mixture is then applied above a marrow-stimulated6
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remains voluminous by impeding platelet-mediated clot re-
traction, in order to more effectively drive subchondral
bone-mediated cartilage repair10,11.
Chitosan is composed of glucosamine and N-acetyl-
glucosamine monomers, is biocompatible, biodegradable,
non-toxic, and has been shown to improve wound healing
in connective tissues of several species12,13. Chitosan in-
duces aggregation and activation of platelets14 and pro-
motes blood coagulation15,16. Furthermore, chitosan is
a polycation that can bind to biological surfaces that are
rich in anionic glycosaminoglycans17, including cartilage11,
and is therefore particularly promising for orthopedic appli-
cations. In dermal wound healing models, chitosan has
been found to induce transient chemotaxis of inﬂammatory
cells18e20 that is often accompanied by an increase in the
synthesis of collagen in the granulation tissue20, by a pro-
cess believed to be partly dependent on secretion of growth
factors by macrophages21. Chitosan is chemoattractive for
endothelial cells in vitro22 and induces angiogenesis in vivo23.
Similarly as in dermal wound healing models, the stimula-
tory effects of chitosan on cell recruitment and angiogenesis
could promote more effective cartilage repair in lesions that
communicate with subchondral bone.
A well known property of chitosan is its solubility at acidic
pH (<6) and insolubility at neutral pH, making its use in so-
lution with living cells and tissues problematic. However,
glycerol phosphate (GP) buffers can be used to bring chito-
san solutions to a cytocompatible near-neutral pH, while
maintaining chitosan solubility24,25. We recently demon-
strated that mixing of this physiological chitosaneGP solu-
tion with whole blood generates a chitosaneGP/blood
solution that coagulates in situ within 15 min, when applied
to cartilage defects10,11. Furthermore, these coagulated
chitosaneGP/blood clots are adhesive and contract much
less than whole blood clots, thereby maintaining a volumi-
nous scaffold10,11. ChitosaneGP/blood implants were
applied to marrow-stimulated chondral defects in sheep
and rabbit cartilage repair models, where they induced
greater ﬁll of chondral defects with repair tissue compared
to marrow-stimulation alone11 and, in addition, produced
a more cellular and hyaline repair cartilage well integrated
with a porous subchondral bone structure10,11. This led us
to hypothesize that chitosaneGP/blood clots stimulated
speciﬁc early events in osteochondral healing that led to
more hyaline repair.
In the current study, we have examined cell recruitment
and repair tissue characteristics at early post-surgical time
points in a rabbit repair model to further understand the in-
ﬂuence of these implants on cartilage repair. We tested
the hypotheses that chitosaneGP/blood implants would
(1) initially reside in the defects and then be completely
degraded without generating chronic inﬂammation, (2) in-
crease bone marrow cell recruitment, (3) increase vascu-
larization of the provisional repair tissue, and (4)
modulate subchondral repair tissue development. For
this, we used a previously developed rabbit model10,
where bilateral trochlear cartilage defects were perforated
with microdrill holes into the subchondral bone, and then
either treated with the chitosaneGP/blood implants or
left to bleed from subchondral bone as the control. Implant
residency and biodegradation, recruitment of host cells,
vascularization of subchondral tissue and osteochondral
healing events were assessed with histochemical stains,
immunohistochemical collagen typing, and stereology
tools at time points ranging from 1 to 56 days post-
surgery.Materials and methods
ANIMALS
Three groups of skeletally mature New Zealand White
(NZW) rabbits (Charles River, St. Constant, QC, Canada)
housed individually in cages were used for the study (Table I).
The housing, care and study protocol were approved by
the Animal Care Committee of the University of Montreal.
The animals were randomized according to sex and weight
for distribution to treatment group and to each time point.
The treated knee (left or right) was also randomized.
PREPARATION OF CHITOSAeGP SOLUTIONS
Chitosans (BioSyntech Inc, Laval, Quebec, Canada) with
degree of deacetylation (DDA) between 77% and 83%
(Table II) were used to treat the three groups of rabbits.
Sterile chitosaneGP solutions were prepared by ﬁrst dis-
solving 150 or 170 mg (after drying) chitosan powder in
9 ml of 66 5 mM HCl (VW3202-2, VWR, Mississauga,
Ontario, Canada) followed by autoclave sterilization, and
addition of 1 ml ﬁlter-sterilized 1.35 M disodium b-glycero-
phosphate (C3H7Na2O6P5H2O) (G-9891, Sigma, Oakville,
Ontario, Canada) to obtain a ﬁnal chitosaneGP solutions
consisting of 1.5% or 1.7% (w/v) chitosan with 135 mM
disodium b-glycerophosphate and 59 mM HCl. The chito-
san concentration, pH and osmolality of the chitosaneGP
solutions used to treat each animal group are indicated in
Table II. ChitosaneGP solutions were distributed in
1.18 ml aliquots into sterile, de-pyrogenized 4 cc Wheaton
glass vials containing six sterile surgical stainless steel
beads (0.39 g each, #9736, Salem Specialty Ball Co, Can-
ton, CT, USA), ﬂash-frozen with liquid nitrogen and stored
at 80C until use. The steel beads aided in mixing with
blood during manual shaking as described below.
SURGICAL PROCEDURES
Following intramuscular (IM) injection of an anesthetic
cocktail (ketamineexylazineebuprenorphine), the animals
were placed under gas anesthesia with 3% isoﬂuranee8%
Table I
Number of animals evaluated in each group at each time point
Group Totalz
1* 2y 3y
Age at surgery
8 Months 15 Months 8 Months
Average weight at surgery
4.7 kg 5.0 kg 4.7 kg
Sacriﬁce at 1 day 3 2 e 5
Sacriﬁce at 3 days 3 2 e 5
Sacriﬁce at 7 days 3 2 e 5
Sacriﬁce at 14 days 3 3 2 8
Sacriﬁce at 21 days e e 3 3
Sacriﬁce at 35 days e e 3 3
Sacriﬁce at 56 days e e 3 3
Total 12 9 11 32
*Sixty minutes recovery from anesthesia.
yFour hours recovery from anesthesia.
zMale and female rabbits were equally distributed among all
groups at each time point studied.
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Each rabbit underwent sequential bilateral arthrotomies
with each trochlea receiving a 3.5 mm 4.5 mm defect cre-
ated by using 1.5 mm and 2.75 mm ﬂat blades (10035-05
and 10035-10, Fine Science Tools, North Vancouver, B.C.,
Canada) to scrape off cartilage within the rectangular defect.
This debridement appeared to leave the calciﬁed cartilage
layer intact since no punctate bleeding was observed from
the bed of the defect immediately following debridement.
However, histological observation at 1 day post-surgery re-
vealed that the calciﬁed cartilage layer was indeed partly de-
brided (see Results). The chondral defects were then drilled
to produce four 0.9 mm diameter drill holes, w4 mm deep
into the subchondral bone in each of the four corners of the
defect [Fig. 1(A)], using a high-speed microdrill (18000-17,
Fine Science Tools, North Vancouver, B.C., Canada) and
a 0.9-mm-diameter drill bit (19007-21, Fine Science Tools,
North Vancouver, B.C., Canada). Continuous irrigation with
phosphate buffered saline (PBS) limited thermal necrosis.
The rabbits from group 1 (Table I) received additional punc-
ture ofmicrodrill holeswith a 261=2gauge needle as previously
described10 which promoted bleeding. One knee per rabbit
was treated by applying the chitosaneGP/blood mixture
(see preparation details below) to the defect. Treatment
with the implant vs control was alternated between the right
knees and left knees in all groups. Non-resorbable prolene
sutures (BEC367251, Dufort Lavigne, Montreal, Quebec,
Canada) were used to close the capsule, fascia and skin.
The rabbits from group 1 recovered within 1 h post-surgery.
In order to prevent sudden movement immediately following
surgery, the rabbits from groups 2 and 3 received three se-
quential IM injections of ketamineexylazine and recovered
Table II
Characteristics of chitosans and chitosaneGP solutions used to
make chitosaneGP/blood implants for each of the three groups of
animals
Group 1 2 3
Chitosan batch PCCH0002 PCCH00025 CH10064
DDA of chitosan (%) 78.5 77.1 82.6
Endotoxin units
per mass of chitosan (EU/g)
<3000 <375 <500
Chitosan concentration (w/v)
in chitosaneGP solution (%)
1.7 1.5 1.5
pH of chitosaneGP solution 6.82 6.82 6.75
Osmolality (mOsm/kg)
of chitosaneGP solution
520 464 444within 4 h post-surgery. All animals were given twice daily in-
jection of buprenorphine analgesic for 2 days and were al-
lowed unrestricted ambulation. Animals were sacriﬁced at
the designated time points (1e56 days post-surgery) using
an overdose of sodium pentobarbital (381, CDMV, St-Hya-
cinthe, Quebec, Canada). Synovial ﬂuid smears were taken
from each knee at necropsy and stained with May-Gru¨n-
wald-Giemsa (MG-1L and GS-1L, Sigma, Oakville, Ontario,
Canada) to obtain differential leukocyte count. Blood was
taken from the rabbits at surgery and immediately prior to sac-
riﬁce toobtain complete bloodcount (CBC), differential leuko-
cyte count and platelet count. One rabbit from group 2
sacriﬁced at 7 days post-surgery exhibited marked blood
and bone marrow neutrophilia as well as increased blood
platelet levels when compared to other rabbits. This rabbit
was removed from further analysis due to suspicion of infec-
tion. No treatment-speciﬁc effusions or other overt signs of in-
fection were seen for the remaining rabbits.
PREPARATION AND APPLICATION OF CHITOSANeGP/BLOOD
MIXTURE
Immediately prior to mixing and application of the im-
plants, autologous blood was aseptically withdrawn from
the rabbit ear artery and 3.5 ml added to the vial containing
1.18 ml sterile chitosaneGP solution and steel beads. For
mixing, the vial was closed and shaken vigorously by hand
for 10 s. The chitosaneGP/blood mixtures consisted of au-
tologous blood mixed with the chitosaneGP solutions in
a 3:1 ratio to yield ﬁnal concentrations of 0.4% (w/v) chitosan
and 34 mM disodium b-glycerophosphate. A 3 cc syringe
equipped with an 18 gauge needle was used to withdraw ap-
proximately 3 ml of the chitosaneGP/blood solution and one
hanging drop of this solution was applied to the drilled carti-
lage defect [Fig. 1(B)]. In 23 of 33 treated defects, the liquid
implant ﬂowed outside the defect and was in potential con-
tact with other joint tissues. Coagulation was allowed for
5e8 min before closing the knee. All implants formed a solid
clot covering the entire defect before closing the knee.
HISTOPROCESSING AND STAINING OF OSTEOCHONDRAL
TISSUES
After sacriﬁce, the distal portions of the femurs were clip-
ped off using a bone cutter and ﬁxed in 4% (w/v) parafor-
maldehyde (P-6148, Sigma, Oakville, Ontario, Canada),
0.1 M sodium cacodylate (BP 325-50, Fisher Scientiﬁc,
St-Laurent, Quebec, Canada), pH 7.3 at room temperatureControl
A
Treated
I
B
Fig. 1. Trochlear cartilage defects were microdrilled and either left alone as untreated controls (A) or ﬁlled with chitosaneGP/blood implants
(B). The image in (B) was taken at 5 min after implant delivery.
319Osteoarthritis and Cartilage Vol. 15, No. 3for 24 h and then placed at 4C for a further 48 h. The fe-
murs were decalciﬁed in 10% (w/v) ethylenediaminetetra-
acetic acid (EDTA) (ED4SS, Sigma, Oakville, Ontario,
Canada) in PBS with 0.1% (w/v) paraformaldehyde pH
7.2 for 9 weeks at 4C. The condyles were trimmed off
and the trochlea was prepared for cryosectioning as previ-
ously described26. Cryosections (10e12 mm thickness)
were taken (Microm, Model Cryo-Star HM 560 M) and col-
lected on SuperFrost Plus slides (12-550-15, Fisher Scien-
tiﬁc, St-Laurent, Quebec, Canada).
For Safranin O/Fast Green staining, the sections were se-
quentially immersed in 0.04% (w/v) Fast Green (F-7252,
Sigma, Oakville, Ontario, Canada) and 0.1% (w/v) Safranin
O (S-2255, Sigma, Oakville, Ontario, Canada) in water. For
Gomori Trichrome staining, the sections were immersed in
0.6% (w/v) Chromotrope 2R (C-3143, Sigma, Oakville, On-
tario, Canada) and 0.3% (w/v) Fast Green in 0.6% (w/v)
phosphotungstic acid (P-4006, Sigma, Oakville, Ontario,
Canada).
COLLAGEN TYPING OF OSTEOCHONDRAL TISSUES BY
IMMUNOHISTOCHEMISTRY
Cryosections were subjected to antigen retrieval27 by
boiling in 10 mM Tris pH 10 and enzymatic pre-treatment
with 2.5% (w/v) hyaluronidase EC 3.2.1.35 (H-3506,
Sigma, Oakville, Ontario, Canada) in PBS. Sections were
blocked with 20% (v/v) goat serum (G-9023, Sigma, Oak-
ville, Ontario, Canada) in PBS with 0.1% Triton X-100 for
60 min at room temperature and incubated with the pri-
mary antibody of interest diluted with 10% goat serum in
PBS with 0.1% Triton X-100. The primary antibodies
were (1) monoclonal anti-collagen type I IgG1 clone
COL-1 diluted to 37 mg/ml (C-2456, Sigma, Oakville, On-
tario, Canada), (2) monoclonal anti-collagen type II IgG1
diluted 1:10 (II-II6B3, DSHB, Iowa, USA), and (3) monoclo-
nal anti-collagen type X IgM clone COL-10 diluted to 5 mg/
ml (C-7974, Sigma, Oakville, Ontario, Canada). Sections
were rinsed and incubated with biotinylated goat anti-
mouse IgG (Fab speciﬁc) (B-7151, Sigma, Oakville, On-
tario, Canada) diluted to 22 mg/ml with 10% goat serum in
PBS with 0.1% Triton X-100 for 60 min at room tempera-
ture. Histochemical detection was performed with the Vec-
tastain ABC-Alkaline Phosphatase (AP) system and AP
Red Substrate kit (AK-5000 and SK-5100, Vector Labora-
tories Inc, Burlington, Ontario, Canada). Exclusion of pri-
mary antibody or use of isotype-matched immunoglobulin
(Ig) resulted in no staining. All sections were counter-
stained with Weigert Iron Hematoxylin (HT-10-7 and
HT-10-9, Sigma, Oakville, Ontario, Canada), rapidly dehy-
drated in graded ethanol and mounted in Permount mount-
ing medium (SP15-100, Fisher Scientiﬁc, St-Laurent,
Quebec, Canada).
HISTOMORPHOMETRIC AND STEREOLOGICAL ANALYSES
Digital images of stained sections were acquired with
a Zeiss Axiolab microscope equipped with either a Sony an-
alogue camera, a digital Q Imaging MicroPublisher 3.3 RTV
camera or a digital Hitachi HV-F22F camera. Software for
histomorphometric and stereological analyses included
Northern Eclipse (Mississauga, Ontario, Canada) and BIO-
QUANT OSTEO (Nashville, TN, USA).
The extent of defect debridement was quantiﬁed at 1 day
post-surgery (n¼ 10 defects) by measuring the proportion
of the defect covered with calciﬁed cartilage on oneSafranin O/Fast Green stained transverse section taken
midway between the two pairs of drill holes. The cumulative
width of the calciﬁed cartilage (mm) remaining at the base of
the defect was measured using manual tracing software
Northern Eclipse and then normalized to the total width of
the defect (mm).
The following histomorphometric and stereological mea-
sures were taken for each knee from two transverse sec-
tions, one traversing the proximal set of holes and the
other traversing the distal set of holes. All sections were se-
lected from the central areas of the holes. Some degree of
sampling bias was therefore present in the measurements
involving line or plane stereological probes (Sv, Lv) but
not for point stereological probes (Vv), due to tissue anisot-
ropy and non-random orientation of the sections.
To quantify the average thickness of tissues in the defect,
a projected tidemark was traced manually on Safranin O/Fast
Green stained sections using adjacent intact cartilage on
both sides of the defects as a guide. Then, the total area
(mm2) of tissue present above the projected tidemark was
measured using Northern Eclipse software by thresholding
on tissues ﬁlling the defect and then normalizing to the
width of the defect (mm).
To quantify volume density (Vv¼ volume per tissue vol-
ume) of neutrophils and bone marrow-derived stromal cells
in the microdrill holes, point (P) counting was performed on
Safranin O/Fast Green stained sections, on 0.11 mm2
microscopic ﬁelds taken at three systematic positions
(0.5 mm, 1.25 mm and 2.5 mm below the projected tide-
mark) in each of the four microdrill holes, and applying
Vv¼PPcell type/
P
Ptotal
28. For each knee, Vv was calcu-
lated as the average from 12 ﬁelds. The grid size in the mi-
croscopic ﬁelds was set at 82.28 mm 82.28 mm, so that
the number of points counted for each cell type in each
knee exceeded the minimum stereological requirement of
75e150 points28. Neutrophils were identiﬁed by nuclear
morphology and bone marrow-derived stromal cells by a
ﬁbroblast cell shape.
To quantify length density (Lv¼ length per tissue volume)
of subchondral blood vessels (BV) in Gomori Trichrome
stained sections, BV cross-sections (Q) were counted in
each area of reference (Aref) consisting of 0.11 mm
2 micro-
scopic ﬁelds taken at three systematic positions (0.5 mm,
1.25 mm and 2.5 mm below the projected tidemark) in
each of the four microdrill holes, and applying Lv¼ 2Q/
Aref
28. For each knee, Lv was calculated as the average
from 12 ﬁelds. BV were speciﬁcally identiﬁed by the pres-
ence of erythrocytes.
To quantify volume density (Vv) of subchondral cartilage
in Safranin O/Fast Green stained sections, the area of sub-
chondral cartilage (mm2) was obtained by thresholding on
subchondral cartilage tissue (Safranin O positive) below
the projected tidemark using Northern Eclipse software
and then normalizing to the total area of subchondral tissue
(mm2).
To quantify volume density (Vv) of subchondral bone in
Gomori Trichrome stained sections, the area of subchon-
dral bone (mm2) was obtained by thresholding on subchon-
dral bone (excluding other subchondral tissues such as clot,
ﬁbrous tissue, cartilage and marrow) using BIOQUANT
OSTEO software and then normalizing to the total area of
subchondral tissue (mm2).
To quantify trabecular bone surface density (Sv¼ surface
area per tissue volume) in Gomori Trichrome stained sec-
tions, the perimeter (Per) of subchondral bone (mm) was
obtained by thresholding on subchondral bone (excluding
other subchondral tissues such as clot, ﬁbrous tissue,
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The total area of subchondral tissue (mm2), known as the
area of reference (Aref), was also obtained using BIO-
QUANT OSTEO software. Sv was then calculated asP
Per/
P
Aref 4/p28.
STATISTICAL ANALYSES
Statistical analyses were performed using the paired Stu-
dent’s t-test (pairing treated and untreated for this bilateral
model), analysis of variance (ANOVA) and multivariate
ANOVA in the general linear model, after checking for nor-
mality of data, as well as using non-parametric tests such
as the ManneWhitney U Test and the Wilcoxon matched
pairs test, as implemented in Statistica version 6.1 package
(Statsoft Inc, Tulsa, OK, USA). Since normal probabilityplots suggested most data to respect normality and non-
parametric tests were for the most part concordant with
parametric tests, only results from parametric tests were
presented.
Results
CHITOSANeGP/BLOOD CLOTS WERE PRESENT FOR UP TO 1
MONTH POST-SURGERY
ChitosaneGP/blood implants were solidiﬁed in treated
drilled cartilage defects [Fig. 1(B)], while the contralateral
control defects were drilled and simply allowed to bleed
[Fig. 1(A)]. At 1 day post-surgery, control and treated de-
fects were equally debrided of calciﬁed cartilage in the
zone midway between the drill holes where 53% 31 vsA
Day 1
Day 21
Control Treated
B
C D
I
I
F
Clot
Clot
Clot
Clot
C
C
250 µm
BR
C
250 µm
250 µm
250 µm
250 µm 250 µm
E F
C
C
Day 35
Fig. 2. Safranin O/Fast Green stained sections from control (A, C, E) or treated (B, D, F) defects. A ﬁbrin network (F) covered the control de-
fects at 1 day (A). ChitosaneGP implants (I) stained as dark material in the chondral defects interfacing with the clot in the microdrill holes
(solid arrowheads) and adhering to treated defects at 1 day (solid arrows) (B). In control defects at 21 days, extensive subchondral cartilage
(C) formation was observed (C). By 21 days post-surgery, the implants (I) were still visible in the microdill holes of treated defects where ex-
tensive BR and small cartilage (C) islands were also observed (D). At 35 days, cartilage (C) was found at the top of the microdrill holes in
control (E) and treated (F) defects. Treated (F) repair tissues were already better integrated with the subchondral bone than in controls (E)
due to increased BR with chitosaneGP.
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fects was signiﬁcantly greater than the average thickness of regular
clots in control defects from 1 to 14 days post-surgery (*P< 0.01 us-
ing treatment anddayaspredictors fromday1 to 14, aswell as paired
t-tests for days1, 3 and14).ChitosaneGP implants and regular blood
clots were for the most part degraded by 21 days post-surgery in the
chondral area, after which chondral repair tissue of increasing thick-
ness was synthesized in treated and control defects. Data are ex-
pressed as meanSD with n¼ 5 (Day 1, 3, 7), n¼ 8 (Day 14) and
n¼ 3 (Day 21, 35, 56). Horizontal arrowhead represents the average
thickness of trochlear articular cartilage from unoperated age-
matched rabbits.58% 31, respectively, of the defect base was still covered
with calciﬁed cartilage. Acute repair events were studied in
the sections traversing the microdrill holes where residual
calciﬁed cartilage was only present outside the holes. Con-
trols from 1 to 14 days post-surgery contained a ﬁbrin net-
work and blood clot in the defects and microdrill holes
[Fig. 2(A)]. At these same time points, chitosaneGP im-
plants were detected in treated defects as dense material
staining a dark color with Fast Green29 which interfaced
with the clot at the top of the microdrill holes and adhered
to the defects [Fig. 2(B)]. All but one treated defect (23 of
24) taken between 1 and 14 days post-surgery contained
chitosaneGP implant. At 21 days post-surgery, the residual
chitosaneGP implant could only be detected subchondrally
in the microdrill holes of treated defects [Fig. 2(D)], and was
not observed at all thereafter at 35 and 56 days. Five micro-
drill holes from treatment groups 2 and 3, from a total of 128
microdrill holes (32 treated defects with four holes each)
contained ﬁbrous capsules at 14, 21 and 35 days post-sur-
gery, some of which enclosed chitosan particles (data not
shown). The average thickness of chitosaneGP implants
in the chondral region of treated defects was signiﬁcantly
greater than the average thickness of ﬁbrin clots in control
defects from 1 to 14 days (P< 0.01 for ANOVA comparing
treatment to control taking into account Day as a co-variate
and P< 0.05 for paired t-tests on days 1, 3 and 14) (Fig. 3).
At 21 days, the chondral zones of both control and treated
defects were almost completely devoid of implant, clot, or
repair tissues [Figs. 2(C, D), 3]. By 35 days post-surgery,
repair tissues of continually increasing thickness were de-
tected in the chondral region of treated and control defectsControl Treated
A
25 µm
Day 1
N
Day 7
25 µm
S
N
C
25 µm S
N
N
D
25 µm
I
N
N
B
N
Fig. 4. Safranin O/Fast Green staining showing increased recruitment of neutrophils (N) to the chitosaneGP implants of treated defects (B) vs
to the regular blood clots of control defects (A) at 1 day post-surgery. Some neutrophils in treated defects co-localized around and within im-
plant chitosan particles (I) (B). ChitosaneGP/blood implants increased subchondral recruitment of neutrophils (N) to the microdrill holes of
treated defects (D) vs control defects (C) at 7 days. Bone marrow-derived stromal cells (S) were also observed migrating into the microdrill
holes starting at day 7 (C, D).
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the subchondral bone in treated defects compared to con-
trol defects at 35 days [Fig. 2(F vs E)].
CHITOSANeGP/BLOOD IMPLANTS INCREASED CELL
RECRUITMENT
At 1 day post-surgery, neutrophils (N) were observed in
the chondral region of all treated defects, and some neutro-
phils were co-localized with chitosan particles and aggre-
gates [Fig. 4(B)]. Fewer neutrophils were recruited to the
ﬁbrin clots of control defects [Fig. 4(A)]. Neutrophils were
seldom observed in the subchondral repair tissue of control
defects after 7 days [Fig. 4(C)] while an abundance of neu-
trophils was seen between 3 and 21 days in treated defects
[Fig. 4(D)]. ChitosaneGP/blood implants increased volume
density (Vv) of neutrophils in the microdrill holes of treated
defects until 21 days post-surgery (P< 0.001 at day 3,
P< 0.01 at day 7 and P< 0.05 at day 14 for paired t-tests)
[Fig. 5(A)]. Synovial ﬂuid leukocyte differential proﬁles also
showed a signiﬁcant increase in the proportion of neutro-
phils in treated knees compared to control knees from 3
to 21 days post-surgery, which returned to normal at
35e56 days (data not shown).
Bone marrow-derived stromal cells were observed mi-
grating into the microdrill holes of control and treated de-
fects starting at 7 days [Fig. 4(C, D)]. Volume density (Vv)
of bone marrow-derived stromal cells was signiﬁcantly
higher in microdrill holes of control defects at 7 days post-
surgery (P< 0.05 using the paired t-test), but was higher
in treated defects from 14 days post-surgery and thereafter
(P< 0.05 using the paired t-test on day 21; also P¼ 0.072
from ANOVA of days 14e56 using Day as a co-variate)
[Fig. 5(B)]. Numerical integration of total numbers of stromal
cells recruited to sampled sites up to day 56 indicated a net
increase of 35% in stromal cells recruited to treated defects
vs control.
CHITOSANeGP/BLOOD IMPLANTS INCREASED
SUBCHONDRAL VASCULARIZATION
New BV ﬁlled with erythrocytes were ﬁrst observed in the
bottom of the microdrill holes of treated and control defects
at 7 days post-surgery. By day 14, greater numbers of BV
were observed in the provisional repair tissue of microdrill
holes below treated defects [Fig. 6(B, D)] compared to con-
trols [Fig. 6(A, C)]. Length density (Lv) of BV was higher in
microdrill holes of treated defects from 14 to 35 days post-
surgery (P< 0.05 for ANOVA using all days taking into ac-
count Day as a co-variate, while P< 0.05 for the paired
t-test at 14 days post-surgery) (Fig. 7).
CHITOSANeGP/BLOOD IMPLANTS DELAYED AND PARTLY
INHIBITED SUBCHONDRAL CARTILAGE FORMATION WHILE
PROMOTING SUBCHONDRAL BONE REMODELING (BR)
Subchondral cartilage formation initially occurred in themi-
crodrill holes of six of eight control defects at 14 days
[Fig. 8(A)]. At 21 days post-surgery, cartilage formation could
be observed throughout themicrodrill holes of control defects
[Fig. 2(C)]. Treated defects were almost devoid of subchon-
dral cartilage at 14 days [Fig. 8(B)] and only contained small
islands of subchondral cartilage at 21 days [Fig. 2(D)]. Sub-
chondral cartilage volume density (Vv) was therefore higher
in control defects at 14 and 21 days post-surgery (P< 0.05
by the paired t-test at 14 days post-surgery) [Fig. 9(A)].Subchondral cartilage formation was followed by chondro-
cyte hypertrophy, as revealed by type X collagen immunos-
taining (data not shown), endochondral ossiﬁcation and
terminal differentiation to bone. By 35 days post-surgery,
subchondral cartilage was observed in treated and control
defects in equal quantities [Fig. 9(A)], near the top of the mi-
crodrill holes [Figs. 2(E, F), 9(A)].
New woven bone (NWB) formation was initiated in con-
trol and treated defects at 7 days, and was initially re-
stricted to the bottom of microdrill holes. Starting at 14
days post-surgery, chitosaneGP/blood implants showed
much more extensive remodeling of cancellous bone in
areas surrounding the microdrill holes [Figs. 2(D), 8(D)].
Treatment was a signiﬁcant predictor of increased trabec-
ular bone surface density (Sv) below defects from 14 to
56 days post-surgery (P< 0.05 from ANOVA with Day
as a co-variate between 14 and 56 days) [Fig. 9(B)].
There was no difference in total bone volume density
(Vv) between control and treated defects at any time
point (data not shown).
Fig. 5. Volume density (Vv) of neutrophils (N) in microdrill holes was
higher in treated defects up to 21 days post-surgery (A) (*P< 0.05 us-
ing Student’s t-test). Volume density (Vv) of bone marrow-
derived stromal cells (S) was higher in microdrill holes of control
defects at 7 days post-surgery (*P< 0.05 using the paired t-test) but
thereafter was greater in treated defects (*P< 0.05 using the paired
t-test on day 21; also P¼ 0.072 using ANOVA for days 14e56 with
Day as a co-variate) (B). Data are expressed as meanSD with
n¼ 5 (Day 1, 3, 7), n¼ 8 (Day 14) and n¼ 3 (Day 21, 35, 56).
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Fig. 6. Gomori Trichrome staining showing subchondral BV in the microdrill holes of control defects (A, C) and treated defects (B, D) at 14
days. Increased BR (solid arrowheads) including resorption and synthesis in treated (B) vs control (A) defects was also observed. Dashed
lines indicate approximate borders of the original microdrilled holes. C and D are higher magniﬁcation photos of the rectangle outlined regions
in A and B, respectively.Discussion
The objective of this study was to examinemodiﬁcations of
early events in osteochondral repair following application of
chitosaneGP/blood implants in cartilage defects that contain
access channels to subchondral bone, in skeletally mature
rabbits. Our previous work has established the ability of
these implants to increase the volume11 and hyaline quality
Fig. 7. Length density (Lv) of BV was higher in microdrill holes of
treated defects from 14 to 35 days post-surgery (*P< 0.05 for AN-
OVA using all days taking into account Day as a co-variate, while
P< 0.05 for the paired t-test at 14 days post-surgery). Data are ex-
pressed as meanSD with n¼ 5 (Day 1, 3, 7), n¼ 8 (Day 14) and
n¼ 3 (Day 21, 35, 56).of cartilage repair tissue10,11, but key events controlling this
improved repair were not previously investigated in detail.
Our results here revealed that chitosaneGP/blood implants
reside for approximately 3 weeks post-surgery in this rabbit
model and that degradation is in part mediated by host-de-
rived neutrophils. During this period, chitosaneGP/blood im-
plants increased subchondral cell recruitment and
vascularization in the microdrill holes. Increased BR and
new bone formation by an intramembranous pathway were
also observed, rather than endochondral ossiﬁcation requir-
ing a cartilaginous intermediate. These subchondral events
preceded cartilage repair tissue synthesis and could explain
the previously described signiﬁcant correlation between po-
rous bone underlying the synthesis of a hyaline repair tissue
in the chondral compartment10.
Microdrilled control defects in this study healed through
a similar sequence to that previously reported in rabbit for
drill or microfracture holes communicating with the cancel-
lous bone2,30,31. Healing in the microdrill holes of control
defects in our model closely resembled healing of 3-mm
diameter osteochondral defects observed previously2, start-
ing with blood clot formation, inﬂammatory and marrow-
derived stromal cell migration, synthesis of a vascularized
granulation tissue, intramembranous bone formation in the
deeper regions of the microdrill holes, as well as subchon-
dral cartilage formation followed by endochondral ossiﬁca-
tion in the more superﬁcial regions of the microdrill holes.
In microdrilled cartilage defects of skeletally mature rabbits,
these events led to the synthesis of bone in the bony com-
partment and of principally ﬁbrocartilaginous repair tissue
emerging from the microdrill holes into the cartilage
compartment2,10,30,31.
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Fig. 8. Type II collagen immunostaining (A, B) detected subchondral cartilage (C) formation in the upper regions of the microdrill holes of con-
trol defects vs continued presence of the chitosaneGP/blood implant (I) in treated defects at 14 days. Type I collagen immunostaining (C, D)
was enhanced in areas of intramembranous NWB formation at the bottom of the microdrill holes, as well as in regions of increased subchon-
dral remodeling of cancellous bone (arrowheads) adjacent to microdrill holes in treated defects (D). Dashed lines indicate approximate borders
of the original microdrilled holes.ChitosaneGP implant residency was conﬁrmed by histol-
ogy in treated defects until 21 days post-surgery (Fig. 2). In
general, more tissue was macroscopically apparent in the
treated defects compared to controls, especially around
the drill holes, which appeared to anchor the implants. Chito-
saneGP clots adhered to defect surfaces at 1 day post-sur-
gery (Fig. 2), extending the previous ﬁnding of adhesion of
chitosaneGP implants to the defect surfaces at 2 h post-
surgery in sheep microfracture defects11. We have previ-
ously shown in vitro that chitosaneGP can physically
stabilize the blood clot by generating clots that retract less
than whole blood clots10. Consistent with this observation
was our ﬁnding here of a greater average thickness of chito-
saneGP implants compared to regular clots in control
defects until 14 days (Fig. 3). Interestingly, most of the chito-
saneGP implants in treated defects and the regular clots in
control defects were degraded by 21 days, and tissue re-
growth into the chondral zone occurred thereafter (Figs. 2,
3). It appears then that early stages of bone marrow-derived
cartilage repair primarily depend on processes occurring in
the subchondral bone and that subsequent tissue repair in
the chondral zone occurs afterwards by an appositional
mechanism, growing up from the subchondral bone.
ChitosaneGP/blood implants increased recruitment of
neutrophils to the microdrill holes of treated defects (Figs.
4, 5) and to the synovial ﬂuid of treated knees, possibly
due to the chemotactic potential of chitosan demonstrated
previously in vitro32,33 and in vivo19,20. Neutrophils appeared
to migrate mainly from the bone marrow in conjunction with
bone marrow-derived stromal cells, but may have also mi-
grated from the vasculature in the granulation repair tissueand from the synovial ﬂuid. Numerous neutrophils were ob-
served co-localizing with chitosan particles and aggregates,
suggesting that these cells are mainly responsible for the
phagocytosis and degradation of the implants. Some micro-
drill holes from treated defects contained ﬁbrous tissues sur-
rounding chitosan particles that resolved over time. Fibrous
capsules like these have been shown to form around slowly
degradable biomaterial implants34, suggesting that ideal
residency for the chitosan implant may be similar to the res-
idency of the normal clot, as we observed here. Neutrophils
are believed to have short life spans, but their survival can
be lengthened by certain cytokines35. Chitosan scaffolds im-
planted in soft-tissue of mice elicited a sustained neutrophil
presence up to 4 weeks post-implantation36. In our model,
neutrophil inﬁltration from the marrow and synovial ﬂuid
ceased by 35 days post-surgery in treated defects, coincid-
ing with the complete degradation of the implant.
ChitosaneGP/blood implants increased subchondral vas-
cularization of granulation tissues in treated defects (Figs. 6,
7) consistent with the ability of chitosan to promote endothe-
lial cell migration in vitro22 and angiogenesis in vivo23. Addi-
tionally, chitosan has been shown to synergistically increase
the proliferative effect of platelet-derived growth factor
(PDGF) on vascular smooth muscle cells37. In our model, in-
creased vascularization occurred simultaneously with a pe-
riod of inﬂammatory cell recruitment, suggesting that these
inﬂammatory cells may secrete factors that promote angio-
genesis. Alternately, increased recruitment of marrow-de-
rived stromal cells may affect angiogenesis. Chitosan has
been shown to stimulate secretion of the angiogenic chemo-
kine interleukin (IL)-8 by ﬁbroblasts in vitro38 and may
325Osteoarthritis and Cartilage Vol. 15, No. 3stimulate local joint ﬁbroblasts to secrete angiogenic factors
as well.
ChitosaneGP/blood implants favored intramembranous
bone formation in the microdrill holes (Figs. 8, 9) rather
than endochondral ossiﬁcation, perhaps through increased
vascularization of the granulation tissue. For example, an
increase in blood supply during distraction osteogenesis
has been associated with intramembranous bone forma-
tion39. Angiogenesis in the microdrill holes appeared to be
directly related to delayed subchondral cartilage formation.
Microdrill holes of control defects had few BV at 14 and
21 days post-surgery and extensive subchondral cartilage
formation. In comparison, microdrill holes of treated defects
had, on average, twice as many BV, continued angiogene-
sis and marrow-derived stromal cell recruitment at the same
time points. Delayed initiation and displacement of chondro-
genesis towards the top of the microdrill holes could explain
in part the more columnar and hyaline tissue found in our
previous study at 56 days10.
Although some BR was observed under our control de-
fects, as has been observed under cartilage defects treated
Fig. 9. Volume density (Vv) of subchondral cartilage [for example C
in Fig. 8(A)] was higher in control defects at 14 and 21 days post-
surgery (A) (*P< 0.05 using the paired t-test on day 14). Surface
density (Sv) of trabecular bone was higher in treated defects com-
pared to controls from day 14 to 56 (B), in a sustained fashion
(*P< 0.05 from ANOVA with Day as a co-variate between days
14 and 56). Data are expressed as meanSD with n¼ 5 (Day 1,
3, 7), n¼ 8 (Day 14) and n¼ 3 (Day 21, 35, 56).with microfracture40, chitosaneGP/blood implants increased
subchondral BR compared to controls (Figs. 2, 8, 9). Other
cartilage repair procedures have been reported to induce
subchondral bone reactions, leading to a net loss of
bone41, invasion of the bony compartment with cartilaginous
and ﬁbrous tissues42, and distortion of the trabecular struc-
ture43. In contrast, we found focal areas of bone resorption
below the implants were quickly replaced with a vascularized
granulation repair tissue and NWB. New bone trabeculae
were ﬁner andmore numerous (Fig. 8), leading to an increase
in trabecular surface density under treated defects (Fig. 9)
without any apparent increase in bone volume density. The
latter is in contrast to increased subchondral bone porosity
found at 8 weeks in a more superﬁcial region (250 mm below
the tidemark)10 compared to our more deeply sampled re-
gions here reaching down to 4 mm below the tidemark, rein-
forcing the importance of accounting for depth when
analyzing subchondral bone responses. Of note, an in-
creased number of multinucleated cells, possibly osteo-
clasts, were observed within bone marrow cavities of
defects treated with chitosaneGP/blood implants in our rab-
bit model at 56 days (unpublished observations), suggesting
that remodeling is still on-going at this early end-point. Taken
together, these observations suggest that chitosaneGP/
blood implants induce angiogenesis and BR which leads to
a porous subchondral bone structure with well vascularized
marrow cavities. The presence of this type of porous and vas-
cularized subchondral bone may be essential for effective
cartilage repair in methods that rely on bone marrow-medi-
ated cartilage regeneration10,11.
Solutions of chitosan in GP can be mixed with freshly
drawn autologous blood and applied to debrided cartilage
lesions containing conduits to subchondral marrow spaces
to facilitate cartilage repair. Previous studies showed that
chitosaneGP/blood implants solidify and adhere to cartilage
defects, inhibit clot retraction and lead to more chondral re-
pair tissue with greater hyaline quality. The current study
added to this knowledge that chitosaneGP/blood implants
increase cell recruitment, transient vascularization and re-
modeling in the subchondral bone region and suggests
that these three events are in part responsible for increased
quantity and quality of repair tissue in the chondral zone.
These results highlight the importance of examining acute
and intermediate events in cartilage repair, the predominant
role of subchondral bone in effecting cartilage repair, and
the potential beneﬁts of adopting a cartilage repair strategy
that modulates acute and intermediate events in the sub-
chondral bone in order to improve ﬁnal cartilage repair
outcome.
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